Highest-risk precancerous condition of esophagus eliminated in 90 percent
SUNNYVALE, Calif., May 15 /PRNewswire/ -- BARRX Medical, Inc., the global technology leader for treating precancerous conditions of the digestive tract, today announced that 90.2 percent of the patients in a multi-center U.S. study were free of the highest-risk of Barrett's esophagus after having a non-surgical, endoscopic treatment using the HALO360 ablation system. Barrett's esophagus afflicts more than three million U.S. adults and is a complication of gastroesophageal reflux disease (GERD). The abnormal Barrett's tissue is the precursor to esophageal cancer (adenocarcinoma), which has the fastest rising incidence of all cancers in the U.S.
This study is currently online and appearing in an upcoming issue of Gastrointestinal Endoscopy, a medical journal for gastroenterologists who perform advanced diagnostic and therapeutic endoscopic procedures. In the report titled, "Circumferential Ablation of Barrett's Esophagus Containing High-Grade Dysplasia: A U.S. Multi-Center Registry," 142 patients with the most advanced stage of Barrett's esophagus -- called high grade dysplasia -- were treated with the HALO360 Ablation System and had a 90.2% clearance rate. This unique, catheter-based technology applies a controlled amount of heat energy to the diseased tissue of the esophagus, resulting in restoration of a normal esophageal lining in the majority of patients.
"The results of our trial confirm that this sub-type of Barrett's
esophagus having the highest-risk of becoming cancer can be safely and
effectively treated," said Abbott Northwestern Chief of Gastroenterology
and Associate Professor of Medicine, Robert Ganz, M.D., of Minneapolis, MN.
Dr. Ganz led the study which was co-authored with specialists at 15 other
leading U.S. medical centers. "We're confident this treatment can sharply
reduce the number of patients who have a
|SOURCE BARRX Medical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved